PHI-501, a novel pan-RAF/DDRs dual kinase inhibitor, overcomes BRAF or MEK inhibitor resistance in melanoma

被引：0
|
作者：
Kim, Sue Min
Park, Jung Hee
Nam, Ky-Youb
Han, June H-J
Kim, Kyu-Tae
Yoon, Jeong Hyeok
Sengupta, Sandip
Sim, Taebo
Shin, Sang Joon
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-411
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
411
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Dual mTOR kinase inhibitor overcomes rapamycin resistance in vitro
    Dai, Yao
    Zhao, Li
    Siemann, Dietmar
    CANCER RESEARCH, 2015, 75
  • [22] Anti-cancer effects of a novel Pan-RAF inhibitor in a hepatocellular carcinoma cell line
    Wang, Wei
    Xu, Bo
    Li, Qixiang
    Jiang, Dechun
    Yan, Suying
    MOLECULAR MEDICINE REPORTS, 2018, 17 (04) : 6185 - 6193
  • [23] Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case report
    Kattan, Joseph
    Kattan, Clarisse
    Farhat, Fadi
    Assi, Tarek
    ANTI-CANCER DRUGS, 2019, 30 (10) : 1052 - 1054
  • [24] Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor
    Huestis, Malcolm P.
    Dela Cruz, Darlene
    DiPasquale, Antonio G.
    Durk, Matthew R.
    Eigenbrot, Charles
    Gibbons, Paul
    Gobbi, Alberto
    Hunsaker, Thomas L.
    La, Hank
    Leung, Dennis H.
    Liu, Wendy
    Malek, Shiva
    Merchant, Mark
    Moffat, John G.
    Muli, Christine S.
    Orr, Christine J.
    Parr, Brendan T.
    Shanahan, Frances
    Sneeringer, Christopher J.
    Wang, Weiru
    Yen, Ivana
    Yin, Jianping
    Siu, Michael
    Rudolph, Joachim
    ACS MEDICINAL CHEMISTRY LETTERS, 2021, 12 (05): : 791 - 797
  • [25] A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma
    Gopal, Y. N. Vashisht
    Gammon, Seth
    Prasad, Rishika
    Knighton, Barbara
    Pisaneschi, Federica
    Roszik, Jason
    Feng, Ningping
    Johnson, Sarah
    Pramanik, Snigdha
    Sudderth, Jessica
    Sui, Dawen
    Hudgens, Courtney
    Fischer, Grant M.
    Deng, Wanleng
    Reuben, Alexandre
    Peng, Weiyi
    Wang, Jian
    McQuade, Jennifer L.
    Tetzlaff, Michael T.
    Di Francesco, Maria E.
    Marszalek, Joe
    Piwnica-Worms, David
    DeBerardinis, Ralph J.
    Davies, Michael A.
    CLINICAL CANCER RESEARCH, 2019, 25 (21) : 6429 - 6442
  • [26] A novel Raf kinase inhibitor blocks the Raf/MEK/ERK pathway in tumor cells.
    Wilhelm, S
    Kennure, N
    Housley, T
    Katz, M
    Wood, J
    Lyons, J
    Taylor, R
    Knepper, M
    Roscoe, W
    Bollag, G
    CLINICAL CANCER RESEARCH, 2000, 6 : 4547S - 4547S
  • [27] Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion
    Menzies, Alexander M.
    Yeh, Iwei
    Botton, Thomas
    Bastian, Boris C.
    Scolyer, Richard A.
    Long, Georgina V.
    PIGMENT CELL & MELANOMA RESEARCH, 2015, 28 (05) : 607 - 610
  • [28] Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells
    Fisher, Matthew L.
    Grun, Daniel
    Adhikary, Gautam
    Xu, Wen
    Eckert, Richard L.
    ONCOTARGET, 2017, 8 (66) : 110257 - 110272
  • [29] Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma
    Ma, Xiao-Hong
    Piao, Sheng-Fu
    Dey, Souvik
    Mcafee, Quentin
    Karakousis, Giorgos
    Villanueva, Jessie
    Hart, Lori S.
    Levi, Samuel
    Hu, Janice
    Zhang, Gao
    Lazova, Rossitza
    Klump, Vincent
    Pawelek, John M.
    Xu, Xiaowei
    Xu, Wei
    Schuchter, Lynn M.
    Davies, Michael A.
    Herlyn, Meenhard
    Winkler, Jeffrey
    Koumenis, Constantinos
    Amaravadi, Ravi K.
    JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (03): : 1406 - 1417
  • [30] THE ROLE OF SOD2 AND ROS IN BRAF/MEK INHIBITOR RESISTANCE IN BRAF MUTANT MELANOMA.
    Yuan, L.
    Mishra, R.
    Patel, H.
    Alanazi, S.
    Wei, X.
    Ma, Z.
    Garrett, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S53 - S53
12345